Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.62 |
| ▸ | VEGFA | P15692 | 1/20 | 0.62 |
| ▸ | PTGER3 | P43115 | 12/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1876678 | 0.81 | ALDH1A1 (0.56) | EGLN1VEGFAPTGER3LMNAKDM4E | |
| SCHEMBL4990176 | 0.80 | PTGER3 (0.60) | PTGER3LMNAMAP3K14KDM4EALDH1A1 | |
| SCHEMBL14302460 | 0.80 | PTGER3 (0.52) | PTGER3LMNAMAP3K14KDM4EALDH1A1 | |
| SCHEMBL13120806 | 0.80 | LMNA (0.51) | PTGER3LMNAMAP3K14KDM4EALDH1A1 | |
| SCHEMBL272388 | 0.80 | EGLN1 (0.75) | EGLN1VEGFALMNAKDM4EALDH1A1 | |
| SCHEMBL1770401 | 0.77 | EGLN1 (1.00) | EGLN1VEGFALMNAKDM4EALDH1A1 | |
| SCHEMBL28003319 | 0.76 | POLB (0.69) | PTGER3LMNAMAP3K14KDM4EALDH1A1 | |
| SCHEMBL4703319 | 0.76 | PTGER3 (1.00) | PTGER3KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL6837441 | 0.76 | PTGER3 (0.46) | PTGER3LMNAMAP3K14KDM4EALDH1A1 | |
| SCHEMBL14328169 | 0.74 | EGLN1 (0.71) | EGLN1VEGFALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496082-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | Aerpio Therapeutics Inc. (US) | 2012-09-12 | — | — | EP | claimed |
| WO-2011057112-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | claimed |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3698794-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | Aerpio Therapeutics, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3603644-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3603644-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-2952192-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2952192-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| WO-2011057121-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057121-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | ALPI, SI, SLC10A2 | EGLN1 2861/4885VEGFA 4546/4885PTGER3 69/4885 |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885VEGFA 551/4885PTGER3 2633/4885 |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | EGLN1 8/4885VEGFA 20/4885PTGER3 2835/4885 |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885VEGFA 551/4885PTGER3 2633/4885 |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885VEGFA 551/4885PTGER3 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.